Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms - NEN Dual 64Cu-DOTATATE 18FDG PET

Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet0 个研究点目标入组 200 人开始时间: 2021年12月15日最近更新: 2024年8月26日

适应症

试验速览

暂无简介。

•1) Age of or above 18 years
•2) Histopathologically verified gastro-pancreatic neuroendocrine neoplasm
•3) Patients with unknown primary tumor with metastases with verified neuroendocrine neoplasm positive histopathological examination suggesting gastro-pancreatic origin
•4) Must be able to read and understand the patient information in Danish and to give informed consent
•5) WHO Performance status 0-2
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 150
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 50

•1) Pregnancy
•2) Breast-feeding
•3) Weights more than the maximum weight limit for the PET/CT bed of the scanner (140 kg)
•4) Uncontrolled diabetes
•5) Uncontrolled infection
•6) Exacerbation in autoimmune diseases
•7) Other active cancer disease
•8) Conditions or diseases (e.g. uncontrolled Parkinson’s disease) making the patient unable to lie still in the scanner
•9) Severe claustrophobia
•10) Localized neuroendocrine neoplasms of the appendix, the rectum measuring < 1 cm, and ECL-omas of the stomach
•11) History of allergic reaction attributable to compounds of similar chemical or biologic composition to 18FDG or 64Cu-DOTATATE

发起方

Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet